Cardano Risk Management B.V. reduces position in Merck & Co., Inc. $MRK

June 26, 2026

Cardano Risk Management B.V. significantly decreased its investment in Merck & Co., Inc. during the first quarter of this year, reducing its stake by 89.8%. This move involved selling 8.64 million shares, resulting in the firm retaining only 979,681 shares valued at approximately $117.8 million. Despite this reduction in holdings, the sentiment among analysts towards Merck remains predominantly positive, with several financial institutions either reiterating or increasing their price targets for the company. MarketBeat’s overall consensus rating for Merck is classified as a “Moderate Buy,” with the average target price set at $128.72.

Merck recently published its quarterly results, which exceeded expectations, demonstrating the company’s strong performance. Additionally, Merck continues to profit from recent regulatory successes related to Keytruda combinations. As part of its investor-friendly strategy, Merck also pays a quarterly dividend of $0.85 per share, resulting in an annual yield of 2.7%.

Given the current landscape, investors might be interested in exploring alternative investment opportunities beyond Merck & Co., Inc. By diversifying their portfolios, investors can potentially mitigate risk and maximize returns over time. While Merck remains a solid investment option, exploring other stocks may present additional growth opportunities in the market.